U.K. Bexsero campaign cuts men B cases in half, building GSK's case in other countries

Bexsero

One year into a meningitis B vaccination campaign in the U.K., GlaxoSmithKline ($GSK) is touting promising preliminary data that may help to build the vaccine’s case for other countries considering similar programs.

The first-of-its-kind vaccination push led to a 50% reduction in meningitis B cases after 10 months, when compared with a four-year average, GSK said Monday. Bexsero was estimated to be 83% effective against any men B strain and 94% effective against preventable strains. What’s more, more 90% of eligible infants received the two doses.

The preliminary results may help inform other countries’ decisions about men B immunization campaigns, GSK vaccines CMO Thomas Breuer said in a statement. The new data “substantially advance our understanding" of meningitis B vaccines' usefulness in the real world, he said.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Early results from the immunization campaign come as GSK works to capitalize on its multibillion-dollar asset swap with Novartis ($NVS), which brought Bexsero and other vaccines under the GSK umbrella. So far, its efforts seem to be paying off: The pharma giant last month reported that the ex-Novartis business is set to soar past old expectations. Glaxo projects 2016 sales 9 times higher than Novartis’ previous estimates, and GSK's actual sales in 2015 were 5 times higher than Novartis projections.

To get things started following the deal close, GSK settled a price standoff between Novartis and the U.K. for the Bexsero campaign; reports said the parties came to an agreement of £20 per dose. As the campaign ramped up, demand was high enough that there was a brief shortage of the vaccine at U.K. private clinics.

Also helping drive demand along the way were men B outbreaks in the U.S and a social media furor in the U.K. over the death of a toddler earlier this year, Bloomberg reported.

After the latest data were released, Meningitis Research Foundation head of research Linda Glennie echoed GSK's enhanced case for the shot. "[W]e hope that other countries burdened by meningitis B will now consider protecting their people from this deadly disease," Glennie said in a statement.

Bexsero delivered £115 million in sales last year for GSK. The company has already passed that benchmark this year, with £62 million in first quarter Bexsero sales and £97 million in the second quarter.

Related Articles:
GSK extracting standout sales from former Novartis vaccine biz
Private clinics seeing shortage of GSK's Bexsero in U.K.
GSK finally seals U.K. Bexsero deal for £20 per dose, report says
Glaxo's Bexsero supply rebounds after demand for MenB jab outstrips supply

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.